Abstract:Hypertension is a serious public health problem worldwide. MT-1207, chemically named 3-(4-(4-(1H-benzotriazole-1-yl)butyl)piperazine-1-yl) benzisothiazole hydrochloride, is a new chemical entity that has entered into clinical trial as antihypertensive agent in China. In this paper we report the pharmacological profile of MT-1207 regarding its acute, subacute, and long-term effects on hypertensive animal models, and its actions on isolated organs in vitro as well as its molecular targets. Blood pressure (BP) was measured in conscious animals; amlodipine was taken as a positive control drug. We showed that both single dose of MT-1207 (1.25−20 mg/kg, ig) in spontaneously hypertensive rats (SHR) and MT-1207 (0.25−6 mg/kg, ig) in two-kidney one-clip (2K1C) dogs dose-dependently decreased BP. MT-1207 quickly decreased BP within 5 min after administration; the hypotensive effect lasted for 8 and 12 h, respectively, in SHR and 2K1C dogs without reflex increase in heart rate. Multiple doses of MT-1207 (5 mg · kg−1 · d−1 in SHR; 2 mg · kg−1 · d−1 in 2K1C dogs, for 7 days) significantly decreased BP, slightly reduced heart rate, and both of them recovered after withdrawal. Long-term administration of MT-1207 (10 mg · kg−1 · d−1 for 4 months or more time) produced a stable BP reduction, improved baroreflex sensitivity, reduced renal and cardiovascular damage in SHR, and delayed stroke occurrence and death in stroke-prone SHR. In isolated rat aortic rings precontracted by adrenaline, KCl, noradrenaline or 5-hydroxytryptamine (5-HT), MT-1207 (10−9–10−4 M) caused concentration-dependent relaxation. In a panel of enzyme activity or radioligand binding assays of 87 molecular targets, MT-1207 potently inhibited adrenergic α1A, α1B, α1D, and 5-HT2A receptors with Ki < 1 nM. The antagonism of MT-1207 against these receptors was confirmed in isolated rabbit arteries. We conclude that MT-1207 is a novel and promising single-molecule multitarget agent for hypertension treatment to reduce hypertensive organ damage and stroke mortality.

[Hypotensive Effect of 1-(2,6-dimethylphenoxy)-2-(3,4-dimethoxyphenylethylamino) Propane Hydrochloride].

[Antagonistic Characterization of 1-(2,6-dimethylphenoxyl)-2-(3,4-dimethylphenyl Ethylamino) Propane Hydrochloride on Alpha 1-Adrenoceptor].

Hypotensive Activity of Tetrandrine in Rats

Drug Metabolism-Based Design, Synthesis, and Bioactivities of 1-(2,6-dimethylphenoxy)-2-(3,4-dimethoxyphenylethylamino)propane Hydrochloride (DDPH) Analogs As Α1-Adrenoceptors Antagonists

Hypotensive activity of tetrandrine in rats. Investigation into its mode of action.

The Experimental Study of Decrease Blood Pressure with MN9202

Effects of Daidzein Sulfates on Blood Pressure and Artery of Rats

Design, synthesis and biological evaluation of dehydroabietic acid derivative as potent vasodilatory agents

Hypotensive effects and mechanisms of adrenomendullin(13-52)

Interaction between Dilazep and α-Adrenoceptors

Aberrant and D1 and D3 Dopamine Receptor Transregulation in Hypertension

Effects of DDPH on Reperfusion Induced-Arrhythmia and Cardiac Α-Adre Noceptors

Differential response to chloroethylclonidine in blood vessels of normotensive and spontaneously hypertensive rats: role of alpha 1D- and alpha 1A-adrenoceptors in contraction

Identification of higenamine as a novel α1 -adrenergic receptor antagonist.

Some effects of dihydroergocristine and of phentolamine mesylate on renal function in rats

Blood Pressure Reduction Induced By Low Dose Of Epinephrine Via Different Routes In Rats

Effects of Dexmedetomidine on Cardiovascular Responses During Anesthetic Induction in Hypertensive Patients

Effects of 2,3-Butanedione Monoxime on Blood Pressure, Myocardial Ca2+ Currents, and Action Potentials of Rats

Chiral Selective Effects of Doxazosin Enantiomers on Blood Pressure and Urinary Bladder Pressure in Anesthetized Rats

Pharmacological characterization of MT-1207, a novel multitarget antihypertensive agent

Aberrant D <sub>1</sub> and D <sub>3</sub> Dopamine Receptor Transregulation in Hypertension